185 related articles for article (PubMed ID: 36516249)
41. Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.
Kim JH; Lee SY; Choi JE; Do SK; Lee JH; Hong MJ; Kang HG; Lee WK; Shin KM; Jeong JY; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Thorac Cancer; 2020 Jan; 11(1):19-28. PubMed ID: 31691490
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA expression and clinical outcome of small cell lung cancer.
Lee JH; Voortman J; Dingemans AM; Voeller DM; Pham T; Wang Y; Giaccone G
PLoS One; 2011; 6(6):e21300. PubMed ID: 21731696
[TBL] [Abstract][Full Text] [Related]
43. Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints.
Guan X; Bao G; Liang J; Yao Y; Xiang Y; Zhong X
Semin Cancer Biol; 2022 Nov; 86(Pt 3):346-355. PubMed ID: 35367118
[TBL] [Abstract][Full Text] [Related]
44. Personalized Therapy of Small Cell Lung Cancer.
Schneider BJ; Kalemkerian GP
Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
[TBL] [Abstract][Full Text] [Related]
45. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a.
Sun Y; Hu B; Wang Q; Ye M; Qiu Q; Zhou Y; Zeng F; Zhang X; Guo Y; Guo L
Cell Death Dis; 2018 Jan; 9(2):85. PubMed ID: 29367594
[TBL] [Abstract][Full Text] [Related]
46. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
[TBL] [Abstract][Full Text] [Related]
47. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.
Takakuwa O; Maeno K; Kunii E; Ozasa H; Hijikata H; Uemura T; Kasai D; Ohkubo H; Miyazaki M; Oguri T; Niimi A
Lung Cancer; 2013 Aug; 81(2):174-9. PubMed ID: 23706418
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.
Zhou M; Fan J; Li Z; Li P; Sun Y; Yang Y; Zhou X; Wang J; Wang Y; Qi H; Cai W; Dai X; Hirsch FR
Respir Res; 2019 Nov; 20(1):248. PubMed ID: 31699089
[TBL] [Abstract][Full Text] [Related]
49. New insights into small-cell lung cancer development and therapy.
Wang Y; Zou S; Zhao Z; Liu P; Ke C; Xu S
Cell Biol Int; 2020 Aug; 44(8):1564-1576. PubMed ID: 32281704
[TBL] [Abstract][Full Text] [Related]
50. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
51. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Rijavec M; Silar M; Triller N; Kern I; Cegovnik U; Košnik M; Korošec P
Pathol Oncol Res; 2011 Sep; 17(3):691-6. PubMed ID: 21455636
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition.
Li D; Tong Q; Lian Y; Chen Z; Zhu Y; Huang W; Wen Y; Wang Q; Liang S; Li M; Zheng J; Liu Z; Liu H; Guo L
Cancer Res Treat; 2021 Oct; 53(4):1042-1056. PubMed ID: 33705625
[TBL] [Abstract][Full Text] [Related]
53. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
54. Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC.
Liang X; Lin A; Wang Q; Zhang J; Luo P
Biomed Pharmacother; 2022 May; 149():112909. PubMed ID: 36068773
[TBL] [Abstract][Full Text] [Related]
55. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
56. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
[TBL] [Abstract][Full Text] [Related]
57. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
58. Profilin 2 promotes growth, metastasis, and angiogenesis of small cell lung cancer through cancer-derived exosomes.
Cao Q; Liu Y; Wu Y; Hu C; Sun L; Wang J; Li C; Guo M; Liu X; Lv J; Huo X; Yue J; Du X; Chen Z
Aging (Albany NY); 2020 Nov; 12(24):25981-25999. PubMed ID: 33234737
[TBL] [Abstract][Full Text] [Related]
59. Overcoming Chemotherapy Resistance in SCLC.
Herzog BH; Devarakonda S; Govindan R
J Thorac Oncol; 2021 Dec; 16(12):2002-2015. PubMed ID: 34358725
[TBL] [Abstract][Full Text] [Related]
60. The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing
De S; Lindner DJ; Coleman CJ; Wildey G; Dowlati A; Stark GR
Cancer Res; 2018 May; 78(9):2396-2406. PubMed ID: 29440145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
